SEC Tracker
Get the app

Marpai MRAI

Marpai Q3 FY25: revenue $4.0M, down 42%; diluted EPS −$0.20

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Marpai reported for Q3 FY25, the quarter ended Sep 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$4.0M−42% from $7.0M in Q3 FY2410-Q income statement, on EDGAR
  2. Net income−$3.5MAgainst −$3.6M in Q3 FY2410-Q income statement, on EDGAR
  3. Diluted EPS−$0.20Against −$0.30 in Q3 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$445K−46% from $830K in Q3 FY2410-Q balance sheet, on EDGAR
  5. Cash from operations$634KAgainst −$3.5M in Q3 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Marpai files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8090 and related industry codes: the same peer list as the financial tables.

  1. BioRestorative Therapies BRTX public float $11M, Jun 30, 2025
  2. Mangoceuticals MGRX public float $15M, Jun 30, 2025
  3. Elite Health Systems EHSI public float $24M, Jun 30, 2025
  4. Cryo Cell International CCEL public float $27M, May 31, 2025
  5. Pacific Health Care Organization PFHO public float $3M, Jun 30, 2025